11 – 19 of 19
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2008
-
Mark
Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast conservation surgery with or without postoperative radiotherapy
(
- Contribution to journal › Article
- 2005
-
Mark
Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.
(
- Contribution to journal › Article
- 2003
-
Mark
Improved DNA flow cytometric, DNA ploidy, and S-phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines
(
- Contribution to journal › Article
- 2001
-
Mark
Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens
(
- Contribution to journal › Article
-
Mark
DNA and cell cycle analysis as prognostic indicators in breast tumors revisited
(
- Contribution to journal › Article
- 2000
-
Mark
ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer
2000) In Annals of oncology : official journal of the European Society for Medical Oncology 11(12). p.1545-1550(
- Contribution to journal › Article
-
Mark
Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels
(
- Contribution to journal › Article
- 1998
-
Mark
Different calculation methods for flow cytometric S-phase fraction: prognostic implications in breast cancer? The Swedish Society of Cancer Study Group
(
- Contribution to journal › Article
- 1994
-
Mark
Inter-institutional reproducibility of flow cytometric DNA-analysis in breast carcinomas
(
- Contribution to journal › Article
- « previous
- 1
- 2
- next »